Codexis (STU:4QK) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4QK Codexis Inc STU:4QK
61 GF Score
Price €1.26
GF Value €2.22
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Codexis FFO?

FFO (Funds from operations) only applies to REITs.

STU:4QK
61GF Score
Codexis Inc STU:4QK
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Codexis (STU:4QK) Overvalued in 2026?

Based on GuruFocus' analysis, Codexis stock appears to be undervalued. The current stock price of €1.26 is trading 43.4% below its estimated GF Value™ of €2.22. GuruFocus considers Codexis to be Possible Value Trap.

Key valuation signals for STU:4QK:

  • FFO:
  • GF Value™: €2.22 vs. price of €1.26 (43.4% below fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the STU:4QK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Codexis Business Description

Other Exchanges CDXS:USA0I0X:UK
Address 200 Penobscot Drive, Redwood City, CA, USA, 94063
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
61GF Score

Get the complete analysis for STU:4QK

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.26
Price
€2.22
GF Value